Skip to main content
Erschienen in: Diabetology International 4/2019

15.03.2019 | Original Article

Temporal trends in the prevalence of albuminuria and reduced eGFR in Japanese patients with type 2 diabetes

verfasst von: Nobue Tanaka, Yui Yamamoto, Yoichi Yokoyama, Tomomi Mori, Ko Hanai, Tetsuya Babazono

Erschienen in: Diabetology International | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Changes over time have been shown in renal manifestations in individuals with diabetes in the United States; however, whether the trends are shared across ethnicities is unknown. We conducted this single-center serial cross-sectional study to determine temporal changes in albuminuria and reduced kidney function in Japanese patients with type 2 diabetes. This study included adult Japanese patients with type 2 diabetes who first visited our institute between 2004 and 2013. Temporal changes during the 10 years in the frequency of albuminuria ( ≥ 30 mg/g creatinine) and reduced eGFR ( < 60 mL/min/1.73 m2) were analyzed using the univariate and multivariate logistic regression analyses and Granger causality test. 5331 Japanese patients with type 2 diabetes, 1892 women and 3439 men, with the mean age of 56 ± 13 years, were studied. There was no change in the prevalence of albuminuria in the univariate analysis; however, a significantly decreasing trend was observed after adjustment for several covariates. On the other hand, patients with reduced eGFR significantly increased over time, although the statistical significance disappeared after adjustment for the covariates, including levels of serum uric acid and hemoglobin and use of renin–angiotensin inhibitors. The Granger causality test showed that time series for use of RAS inhibitors and BMI had a causative role in time series for reduced eGFR. In conclusion, prevalence of albuminuria decreased and that of reduced eGFR remained stable after adjustment for clinical characteristics in Japanese patients with type 2 diabetes during the last decade.
Literatur
1.
Zurück zum Zitat Hasslacher CH, Ritz E, Wahl P, et al. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transpl. 1989;4:859–63.CrossRef Hasslacher CH, Ritz E, Wahl P, et al. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transpl. 1989;4:859–63.CrossRef
2.
Zurück zum Zitat Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58:302–11.CrossRef Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58:302–11.CrossRef
3.
Zurück zum Zitat Pugh JA, Medina R, Ramirez M. Comparison of the course to end-stage renal disease of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic nephropathy. Diabetologia. 1993;36:1094–8.CrossRef Pugh JA, Medina R, Ramirez M. Comparison of the course to end-stage renal disease of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic nephropathy. Diabetologia. 1993;36:1094–8.CrossRef
4.
Zurück zum Zitat Ohta M, Babazono T, Uchigata Y, et al. Comparison of the prevalence of chronic kidney disease in Japanese patients with type 1 and type 2 diabetes. Diabet Med. 2010;27:1017–23.CrossRef Ohta M, Babazono T, Uchigata Y, et al. Comparison of the prevalence of chronic kidney disease in Japanese patients with type 1 and type 2 diabetes. Diabet Med. 2010;27:1017–23.CrossRef
5.
Zurück zum Zitat Mongensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983; 32 (Suppl 2): 64-78.CrossRef Mongensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983; 32 (Suppl 2): 64-78.CrossRef
6.
Zurück zum Zitat Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective diabetes study 74. Diabetes. 2006; 55: 1832-8.CrossRef Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective diabetes study 74. Diabetes. 2006; 55: 1832-8.CrossRef
7.
Zurück zum Zitat Yokoyama H, Sone H, Oishi M, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan diabetes clinical data management study (JDDM 15). Nephrol Dial Transpl. 2009;24:1212–9.CrossRef Yokoyama H, Sone H, Oishi M, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan diabetes clinical data management study (JDDM 15). Nephrol Dial Transpl. 2009;24:1212–9.CrossRef
8.
Zurück zum Zitat Kramer CK, Leitão CB, Pinto LC, et al. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007;30:1998–2000.CrossRef Kramer CK, Leitão CB, Pinto LC, et al. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007;30:1998–2000.CrossRef
9.
Zurück zum Zitat Takagi M, Babazono T, Uchigata Y. Differences in risk factors for the onset of albuminuria and decrease in glomerular filtration rate in people with Type 2 diabetes mellitus: implications for the pathogenesis of diabetic kidney disease. Diabet Med. 2015;32:1354–60.CrossRef Takagi M, Babazono T, Uchigata Y. Differences in risk factors for the onset of albuminuria and decrease in glomerular filtration rate in people with Type 2 diabetes mellitus: implications for the pathogenesis of diabetic kidney disease. Diabet Med. 2015;32:1354–60.CrossRef
10.
Zurück zum Zitat Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–7.CrossRef Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–7.CrossRef
11.
Zurück zum Zitat de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–9.CrossRef de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–9.CrossRef
12.
Zurück zum Zitat Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316:602–10.CrossRef Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316:602–10.CrossRef
14.
Zurück zum Zitat Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef
15.
Zurück zum Zitat Granger CWJ. Investigation causal relations by econometric models and cross-spectral methods. Econometrica. 1969;37:424–38.CrossRef Granger CWJ. Investigation causal relations by econometric models and cross-spectral methods. Econometrica. 1969;37:424–38.CrossRef
16.
Zurück zum Zitat Stokes PA, Purdon PL. A study of problems encountered in granger causality analysis from a neuroscience perspective. Proc Natl Acad Sci USA. 2017;114:E7063–E70727072.CrossRef Stokes PA, Purdon PL. A study of problems encountered in granger causality analysis from a neuroscience perspective. Proc Natl Acad Sci USA. 2017;114:E7063–E70727072.CrossRef
17.
Zurück zum Zitat Anderson S, Meier TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612–9.CrossRef Anderson S, Meier TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612–9.CrossRef
18.
Zurück zum Zitat Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993–2000.CrossRef Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993–2000.CrossRef
19.
Zurück zum Zitat Standards of medical care in diabetes–2015: summary of revisions. Diabetes Care. 2015; 38(Suppl 1):S4. Standards of medical care in diabetes–2015: summary of revisions. Diabetes Care. 2015; 38(Suppl 1):S4.
20.
Zurück zum Zitat Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3–15.CrossRef Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3–15.CrossRef
21.
Zurück zum Zitat Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253–390.CrossRef Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253–390.CrossRef
22.
Zurück zum Zitat MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet. 2001;357:455–62.CrossRef MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet. 2001;357:455–62.CrossRef
23.
Zurück zum Zitat Suissa S, Hutchinson T, Brophy JM, et al. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006;69:913–9.CrossRef Suissa S, Hutchinson T, Brophy JM, et al. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006;69:913–9.CrossRef
24.
Zurück zum Zitat Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017;356:j791.CrossRef Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017;356:j791.CrossRef
25.
Zurück zum Zitat Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75:S13–S1616.CrossRef Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75:S13–S1616.CrossRef
26.
Zurück zum Zitat Zhu P, Liu Y, Han L, et al. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS ONE. 2014;9:e100801.CrossRef Zhu P, Liu Y, Han L, et al. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS ONE. 2014;9:e100801.CrossRef
28.
Zurück zum Zitat Babazono T, Hanai K, Suzuki K, et al. Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia. 2006;49:1387–93.CrossRef Babazono T, Hanai K, Suzuki K, et al. Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia. 2006;49:1387–93.CrossRef
29.
Zurück zum Zitat Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004;66:1131–8.CrossRef Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004;66:1131–8.CrossRef
30.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.CrossRef UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.CrossRef
31.
Zurück zum Zitat Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.CrossRef Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.CrossRef
32.
Zurück zum Zitat Zoungas S, Arima H, Gerstein HC. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7.CrossRef Zoungas S, Arima H, Gerstein HC. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7.CrossRef
33.
Zurück zum Zitat Babazono T, Takahashi C, Iwamoto Y. Definition of microalbuminuria in first-morning and random spot urine in diabetic patients. Diabetes Care. 2004;27:1838–9.CrossRef Babazono T, Takahashi C, Iwamoto Y. Definition of microalbuminuria in first-morning and random spot urine in diabetic patients. Diabetes Care. 2004;27:1838–9.CrossRef
34.
Zurück zum Zitat Davey SG, Ebrahim S. ’Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22.CrossRef Davey SG, Ebrahim S. ’Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22.CrossRef
Metadaten
Titel
Temporal trends in the prevalence of albuminuria and reduced eGFR in Japanese patients with type 2 diabetes
verfasst von
Nobue Tanaka
Yui Yamamoto
Yoichi Yokoyama
Tomomi Mori
Ko Hanai
Tetsuya Babazono
Publikationsdatum
15.03.2019
Verlag
Springer Japan
Erschienen in
Diabetology International / Ausgabe 4/2019
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-019-00392-y

Weitere Artikel der Ausgabe 4/2019

Diabetology International 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.